Filing Details
- Accession Number:
- 0001209191-23-011665
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-22 16:30:12
- Reporting Period:
- 2023-02-17
- Accepted Time:
- 2023-02-22 16:30:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-02-17 | 4,498 | $292.85 | 71,107 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2023-02-21 | 21 | $291.01 | 71,086 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-21 | 545 | $292.77 | 70,541 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-21 | 1,100 | $293.74 | 69,441 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-21 | 736 | $294.58 | 68,705 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $292.77 (range $292.25 to $293.07).
- Open market sales reported on this line occurred at a weighted average price of $293.74 (range $293.30 to $294.19).
- Open market sales reported on this line occurred at a weighted average price of $294.58 (range $294.36 to $294.96).
Billionaire Hedge Funds
